[go: up one dir, main page]

EE200000102A - Meetodid ja kompositsioonid teraapiaks, kasutades sekreteeritavaid valke, näiteks interferoon-beetat kodeerivaid geene - Google Patents

Meetodid ja kompositsioonid teraapiaks, kasutades sekreteeritavaid valke, näiteks interferoon-beetat kodeerivaid geene

Info

Publication number
EE200000102A
EE200000102A EEP200000102A EEP200000102A EE200000102A EE 200000102 A EE200000102 A EE 200000102A EE P200000102 A EEP200000102 A EE P200000102A EE P200000102 A EEP200000102 A EE P200000102A EE 200000102 A EE200000102 A EE 200000102A
Authority
EE
Estonia
Prior art keywords
methods
compositions
beta
therapy
genes encoding
Prior art date
Application number
EEP200000102A
Other languages
English (en)
Inventor
G. Barsoum James
Xiao Qin Albert
Original Assignee
Biogen, Incorporated
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen, Incorporated filed Critical Biogen, Incorporated
Publication of EE200000102A publication Critical patent/EE200000102A/et
Publication of EE04873B1 publication Critical patent/EE04873B1/et

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/565—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
EEP200000102A 1997-08-29 1998-08-25 Interferoon-beeta valku kodeerivat geeni sisaldava viirusvektori ja replikatsioonipuudega viirusvektori kasutamine EE04873B1 (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5725497P 1997-08-29 1997-08-29
PCT/US1998/017606 WO1999010516A2 (en) 1997-08-29 1998-08-25 Methods and compositions for therapies using genes encoding secreted proteins such as interferon-beta

Publications (2)

Publication Number Publication Date
EE200000102A true EE200000102A (et) 2000-12-15
EE04873B1 EE04873B1 (et) 2007-08-15

Family

ID=22009467

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200000102A EE04873B1 (et) 1997-08-29 1998-08-25 Interferoon-beeta valku kodeerivat geeni sisaldava viirusvektori ja replikatsioonipuudega viirusvektori kasutamine

Country Status (24)

Country Link
EP (1) EP1007717B8 (et)
JP (3) JP4124565B2 (et)
KR (1) KR100699285B1 (et)
CN (1) CN100342019C (et)
AT (1) ATE316145T1 (et)
AU (1) AU740428B2 (et)
BR (1) BR9812138A (et)
CA (1) CA2300480C (et)
CY (1) CY1105029T1 (et)
CZ (2) CZ299095B6 (et)
DE (1) DE69833264T2 (et)
DK (1) DK1007717T3 (et)
EA (1) EA003256B1 (et)
EE (1) EE04873B1 (et)
ES (1) ES2257817T3 (et)
HU (1) HU224422B1 (et)
IL (2) IL134593A0 (et)
IS (1) IS2318B (et)
NO (1) NO20000990L (et)
NZ (1) NZ503401A (et)
PT (1) PT1007717E (et)
SK (1) SK286821B6 (et)
TR (1) TR200000532T2 (et)
WO (1) WO1999010516A2 (et)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1363676T3 (da) 2001-01-22 2007-07-23 Biogen Idec Inc Fremgangsmåde til forögelse af administration af en terapeutisk nukleinsyre
US8058248B2 (en) * 2001-04-26 2011-11-15 The United States Of America As Represented By The Secretary Of Agriculture Foot and mouth disease virus vaccine comprising interferons
CN1388248A (zh) * 2001-05-25 2003-01-01 钱其军 高效表达干扰素的肿瘤细胞内特异性增殖的腺病毒及其构建方法
EP1835032A1 (en) * 2006-03-14 2007-09-19 Université de Liège A self-inactivating recombinant lentiviral vector for the inhibition of HIV replication
MD36Z (ro) * 2008-12-02 2010-01-31 Василе ЖОВМИР Metodă de tratament diferenţiat al carcinomului ductal in situ neinvaziv al glandei mamare
MD23Z (ro) * 2008-12-02 2010-01-31 Василе ЖОВМИР Metodă de tratament diferenţiat al carcinomului lobular in situ neinvaziv al glandei mamare
MD35Z (ro) * 2008-12-02 2010-01-31 Василе ЖОВМИР Metodă de apreciere a riscului dezvoltării carcinomului neinvaziv in situ al glandei mamare
MD24Z (ro) * 2008-12-02 2010-01-31 Василе ЖОВМИР Metodă de tratament diferenţiat al carcinomului neinvaziv al glandei mamare
CN103505722B (zh) * 2012-06-19 2016-04-13 苏州丁孚靶点生物技术有限公司 干扰素在治疗/预防对常规抗肿瘤疗法有抗性的肿瘤中的用途及相关的产品和方法
US20190125804A1 (en) * 2016-06-15 2019-05-02 Tissue Regeneration Therapeutics Inc. Anti-cancer use of genetically modified human umbilical cord perivascular cells (hucpvc)
AU2020286493A1 (en) * 2019-06-01 2022-01-27 Sivec Biotechnologies, Llc A bacterial platform for delivery of gene-editing systems to eukaryotic cells

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2122519C (en) * 1994-04-29 2001-02-20 Rudolf Edgar Dr. Falk Cancer treatment and metastasis prevention
ATE246252T1 (de) * 1994-08-16 2003-08-15 Crucell Holland Bv Von adenovirus abgeleitete rekombinante vektoren, für gentherapie
US5952221A (en) * 1996-03-06 1999-09-14 Avigen, Inc. Adeno-associated virus vectors comprising a first and second nucleic acid sequence

Also Published As

Publication number Publication date
CZ299095B6 (cs) 2008-04-23
KR100699285B1 (ko) 2007-03-26
HUP0002913A2 (hu) 2000-12-28
IS5374A (is) 2000-02-11
IL134593A0 (en) 2001-04-30
DE69833264T2 (de) 2006-09-28
IL134593A (en) 2007-06-17
KR20010023511A (ko) 2001-03-26
AU9205198A (en) 1999-03-16
SK286821B6 (sk) 2009-06-05
HK1029599A1 (en) 2001-04-06
HU224422B1 (hu) 2005-08-29
JP4219335B2 (ja) 2009-02-04
BR9812138A (pt) 2000-07-18
AU740428B2 (en) 2001-11-01
WO1999010516A2 (en) 1999-03-04
NO20000990L (no) 2000-05-02
EP1007717B8 (en) 2006-05-03
CN1271391A (zh) 2000-10-25
NZ503401A (en) 2003-01-31
EA200000270A1 (ru) 2000-10-30
WO1999010516A3 (en) 1999-05-06
EA003256B1 (ru) 2003-02-27
ES2257817T3 (es) 2006-08-01
IS2318B (is) 2007-11-15
JP3953458B2 (ja) 2007-08-08
JP2004155786A (ja) 2004-06-03
HUP0002913A3 (en) 2003-08-28
EP1007717B1 (en) 2006-01-18
JP2001514010A (ja) 2001-09-11
JP2005225888A (ja) 2005-08-25
JP4124565B2 (ja) 2008-07-23
NO20000990D0 (no) 2000-02-28
EE04873B1 (et) 2007-08-15
CN100342019C (zh) 2007-10-10
SK2482000A3 (en) 2000-08-14
EP1007717A2 (en) 2000-06-14
CA2300480A1 (en) 1999-03-04
CY1105029T1 (el) 2010-03-03
DE69833264D1 (de) 2006-04-06
DK1007717T3 (da) 2006-05-29
CZ297314B6 (cs) 2006-11-15
ATE316145T1 (de) 2006-02-15
CA2300480C (en) 2010-01-05
TR200000532T2 (tr) 2000-11-21
PT1007717E (pt) 2006-06-30
CZ2000733A3 (cs) 2000-06-14

Similar Documents

Publication Publication Date Title
ATE197719T1 (de) Verwendung von mesothelialen zellen in der gentherapie
DE69230993D1 (de) Rekombinante viren vektoren zur expression in muskelzellen
DK1093383T3 (da) Lægemiddelafgivelsessystem omfattende et homeobox-peptid og et cytotoksisk eller antineoplastisk lægemiddel
ATE169959T1 (de) Anthrax-toxin-fusionsproteine und deren verwendungen
UA66417C2 (en) Recombinant adenovirus affecting canines, pharmaceutical composition
FI962154A0 (fi) Koostumus terapeuttisten tuotteiden in vivo valmistusta varten
CY1108459T1 (el) Ακτ-3 νουκλεϊκα οξεα, πολυπεπτιδια, και χρησεις αυτων
EE200000102A (et) Meetodid ja kompositsioonid teraapiaks, kasutades sekreteeritavaid valke, näiteks interferoon-beetat kodeerivaid geene
PT1034185E (pt) Composicoes farmaceuticas que contem a pentraxina longa ptx3
HUP9800635A2 (hu) In vivo exogén transzfekcióra és expresszióra használható gyógyászati kombináció
NO991839L (no) FremgangsmÕter og preparater for utlevering og ekspresjon av interferon-<alfa>-nukleinsyrer
DE69910809D1 (de) Verwendung von OmpA Enterobakterproteinen um zielgerichtet Antigen-Präsentierende Zellen anzusteuern
AU590861B2 (en) New human lymphotoxin (TNF-beta) polypeptides their prepartion and use
DK0676413T3 (da) Inteferon-alfa/beta-bindingsprotein, dets fremstilling og anvendelse
DE69821227D1 (de) Verwendung von papovavirus kapsid-proteinen zur verabreichung therapeutischen agentien in nervzellen
WO2000006735A8 (en) Interferon alpha hybrids
NZ516777A (en) Method for delivery of therapeutic agents, particularly nucleic acids, using a solution of dextrin

Legal Events

Date Code Title Description
HC1A Change of owner name
KB4A Valid patent at the end of a year

Effective date: 20071231

KB4A Valid patent at the end of a year

Effective date: 20081231

MM4A Lapsed by not paying the annual fees

Effective date: 20090825